Modern’a Phase 3 COVID-19 Vaccine Trial to Begin in July

0
790

Fauci: Moderna’s Phase 3 Covid-19 Vaccine Trial Of 30,000 Individuals Will Begin In July

Dr. Anthony Fauci said the Phase 3 trial of Moderna’s experimental COVID-19 vaccine will begin in July and include study of 30,000 patients who will be as young as 18 and include elderly Americans as well.

In an interview Tuesday with the editor of JAMA, Fauci said the trial will include primarily U.S. sites, but also include international sites enrolling 30,000 individuals in a “randomized placebo” controlled trial of Moderna’s vaccine against the Coronavirus strain Covid-19. Moderna’s vaccine candidate is considered in the lead among several efforts by drug and vaccine makers in the battle against the deadly virus.

A phase 3 trial is considered the final stage before potential approval by the U.S. Food and Drug Administration, which would make it available for patients across the country. Moderna last week said it began enrolling 600 healthy participants in a phase 2 clinical trial testing mRNA-1273, the company’s vaccine against the virus that causes Covid-19.



But Fauci confirmed Tuesday the work to begin a much larger phase 3 trial are well underway and will begin early next month.

 

ATTENTION READERS

We See The World From All Sides and Want YOU To Be Fully Informed
In fact, intentional disinformation is a disgraceful scourge in media today. So to assuage any possible errant incorrect information posted herein, we strongly encourage you to seek corroboration from other non-VT sources before forming an educated opinion.

About VT - Policies & Disclosures - Comment Policy
Due to the nature of uncensored content posted by VT's fully independent international writers, VT cannot guarantee absolute validity. All content is owned by the author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners, or technicians. Some content may be satirical in nature. All images are the full responsibility of the article author and NOT VT.